Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Behçet disease-associated uveitis successfully treated with golimumab.

Mesquida M, Victoria Hernández M, Llorenç V, Pelegrín L, Espinosa G, Dick AD, Adán A.

Ocul Immunol Inflamm. 2013 Apr;21(2):160-2. doi: 10.3109/09273948.2012.741744. Epub 2012 Dec 19.

PMID:
23252659
2.

Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Neri P, Zucchi M, Allegri P, Lettieri M, Mariotti C, Giovannini A.

Int Ophthalmol. 2011 Apr;31(2):165-73. doi: 10.1007/s10792-011-9430-3. Epub 2011 Feb 2. Review.

PMID:
21287227
3.

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.

Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.

Ophthalmology. 2014 Mar;121(3):785-96.e3. doi: 10.1016/j.ophtha.2013.09.048. Epub 2013 Dec 17.

PMID:
24359625
4.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
5.

Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.

Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.

J Rheumatol. 2007 May;34(5):1146-50. Epub 2007 Mar 1.

PMID:
17343318
6.

Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.

Leccese P, Latanza L, D'Angelo S, Padula A, Olivieri I.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S93. Epub 2011 Sep 27. No abstract available.

PMID:
21813069
7.

Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.

Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M.

Arthritis Res Ther. 2012 May 1;14(3):R99. doi: 10.1186/ar3824.

8.

Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review.

Calvo-Río V, de la Hera D, Blanco R, Beltrán-Catalán E, Loricera J, Cañal J, Ventosa J, Cifrián JM, Ortiz-Sanjuán F, Rueda-Gotor J, González-Vela MC, González-López M, González-Gay MA.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):864-8. Epub 2014 Oct 2. Review.

PMID:
25288110
9.

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

Bawazeer A, Raffa LH, Nizamuddin SH.

Ocul Immunol Inflamm. 2010 Jun;18(3):226-32. doi: 10.3109/09273948.2010.483314.

PMID:
20482404
10.

The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.

Morris DS, Gavin MP, Sturrock RD.

Adv Exp Med Biol. 2003;528:557-9. No abstract available.

PMID:
12918763
11.

[Research update of anti-TNF-α biologic agents in the treatment of uveitis].

Fan F, Zhou M, Luo Y.

Zhonghua Yan Ke Za Zhi. 2013 Mar;49(3):285-8. Review. Chinese.

PMID:
23866712
12.

Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.

Borrás-Blasco J, Casterá DE, Cortes X, Abad FJ, Rosique-Robles JD, Mallench LG.

Int J Clin Pharmacol Ther. 2015 May;53(5):377-90. doi: 10.5414/CP202171. Review.

PMID:
25345430
13.

[Infliximab treatment for Behçet's disease--beginning of the biological drug era].

Namba K.

Nippon Ganka Gakkai Zasshi. 2010 Feb;114(2):85-6. Japanese. No abstract available.

PMID:
20187504
14.

Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.

Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, Tsuneoka H.

Br J Ophthalmol. 2013 Mar;97(3):338-42. doi: 10.1136/bjophthalmol-2012-302515. Epub 2013 Jan 12.

PMID:
23314623
15.

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.

Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, Bienvenu B, Abad S, Rigolet A, Deroux A, Sene D, Perlat A, Marie I, Feurer E, Hachulla E, Fain O, Clavel G, Riviere S, Bouche PA, Gueudry J, Pugnet G, Le Hoang P, Resche Rigon M, Cacoub P, Bodaghi B, Saadoun D; French Uveitis Network.

Arthritis Rheumatol. 2016 Jun;68(6):1522-30. doi: 10.1002/art.39667.

16.

Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.

Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, Veroz R, Torre I, Hernández FF, Atanes A, Loricera J, González-Vela MC, Palmou N, Hernández JL, González-Gay MA.

Semin Arthritis Rheum. 2016 Aug;46(1):95-101. doi: 10.1016/j.semarthrit.2016.03.002. Epub 2016 Mar 9.

PMID:
27060872
17.

TNF-alpha inhibitors for ankylosing spondylitis.

Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA.

Cochrane Database Syst Rev. 2015 Apr 18;(4):CD005468. doi: 10.1002/14651858.CD005468.pub2. Review.

PMID:
25887212
18.

Adalimumab for sight-threatening uveitis in Behçet's disease.

Mushtaq B, Saeed T, Situnayake RD, Murray PI.

Eye (Lond). 2007 Jun;21(6):824-5. Epub 2006 Apr 7.

PMID:
16601736
19.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

20.

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED.

Rheumatology (Oxford). 2006 Aug;45(8):982-9. Epub 2006 Feb 3.

PMID:
16461435

Supplemental Content

Support Center